Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.[1] He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib.[2][3][4][5] In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.[6]

References

  1. ↑ Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA
  2. ↑ Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com
  3. ↑ Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com
  4. ↑ Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com
  5. ↑ Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM
  6. ↑ Weintraub, Karen (19 May 2013). "MGH, AstraZeneca partner to create new drug combos". Boston Globe. Retrieved 30 January 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.